Nadroparine
Nadroparine Uses, Dosage, Side Effects, Food Interaction and all others data.
Nadroparine is a low molecular weight heparin (LMWH) which, when bound to antithrombin III (ATIII), accelerates the inactivation of factor II and factor Xa. Nadroparine halts the coagulation pathway by inhibiting the activation of thrombin (factor IIa) by factor Xa. The amplification of the fibrin clotting cascade is stopped once factors Xa and IIa are inactivated. It is derived from porcine sources and has a mean molecular size of 5000 daltons. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
Nadroparine is a low molecular weight heparin that is composed of a heterogeneous mixture of sulfated polysaccaride glycosaminoglycan chains. Th mean molecular weight is approximately 4300 daltons. The ratio of anti-Xa activity to anti-IIa is 3.5:1 whereas it is about 1:1 for heparin. Its use should be avoided in patients with a creatinine clearance less than 40mL/min. In these patients, unfractionated heparin should only be used. As for monitoring, active partial thromboplastin time (aPTT) will only increase at high doses of low molecular weight heparins (LMWH). Therefore, monitoring aPTT is not recommended. However, anti-Xa activity can be measured to monitor the efficacy of the LMWH.
Trade Name | Nadroparine |
Generic | Nadroparin |
Nadroparin Other Names | Nadroparina, Nadroparine |
Type | |
Protein binding | Much lower compared to heparin, which has over 90% protein bound. |
Groups | Approved, Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Nadroparine is a low molecular weight heparin used for the prophylaxis of thrombotic events and deep vein thrombosis, and prevent unstable angina and non-Q-wave myocardial infarction.
Nadroparine is used for prophylaxis of thromboembolic disorders and general surgery in orthopedic surgery, treatment of deep vein thrombosis, prevention of clotting during hemodialysis and treatment of unstable angina and non-Q wave myocardial infarction.
Nadroparine is also used to associated treatment for these conditions: Clotting, Deep Vein Thrombosis, Pulmonary Embolism, Thromboembolic Events, Unstable Angina Pectoris, Venous Thromboembolism, Non-q wave myocardial infarction
How Nadroparine works
The mechanism of action for nadroparin is similar to all other LMWHs. Like all LMWHs, nadroparin has a pentasaccharide sequence which binds to ATIII, which potentiates the action of ATIII. This complex greatly accelerates the inactivation of factor Xa and factor IIa. As a result, the coagulation cascade is inhibited.
Toxicity
Osteopenia with extended use, skin necrosis, thrombocytosis, severe immunologically-mediated thrombocytopenia, eosinophilia (rare), calcinosis rarely occurs at the injection site, severe bleeding, transient elevation of liver transaminases.
Food Interaction
- Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.
Volume of Distribution
3.59L
Elimination Route
Absorption is linear. The bioavailability of nadroparin after subcutaneous administration is about 89%.
Half Life
In healthy patients, the half life is between 3.5hrs to 11.2hrs following subcutaneous administration.
Clearance
The clearance of nadroparin is 21.4 +/- 7.0mL/min
Elimination Route
Nadroparine is eliminated via the kidneys through non-saturable mechanisms.
Innovators Monograph
You find simplified version here Nadroparine